MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Parkinson’s disease-associated psychosis in a Brazilian sample: worse cognitive outcomes, higher LEDD and longer disease duration.

    H. Dourado, C. Lobo, G. Procópio, AE. Lima, MA. Silveira, L. de Almeida, IJ. Oliveira, G. Valença (Salvador, Brazil)

    Objective: To describe the prevalence of Parkinson's Disease (PD) associated psychosis (PDAP) at a Brazilian movement disorders outpatient and to evaluate its associated factors. Background:…
  • 2023 International Congress

    Huntington’s disease-like 2 phenotypes: a case series from a Brazilian referral center

    C. Candeias, G. Santos, M. Costa, A. Pessoa Neto, F. Sarmento, B. Veiga, R. Saba, V. Tumas, S. Silva, V. Borges, H. Ferraz (Sao Paulo, Brazil)

    Objective: To describe the clinical phenotypes of Huntington’s disease-like 2 patients in a referral movement disorders (MD) center in Brazil. Background: Huntington's disease-like 2 (HDL2)…
  • 2023 International Congress

    Case of neuroferritinopathy with isolated dystonic leg cramps and normal neuroimaging

    F. Mustafa, K. Sai Krishna, A. Das, A. Garg, A K. Srivastava (NEW DELHI, India)

    Objective: To describe a case of genetically proven neuroferritinopathy with isolated dystonic leg cramps and normal neuro-imaging. Background: Neuroferritinopathy(NF) is an autosomal dominant condition characterized…
  • 2023 International Congress

    Subanesthetic infusion of ketamine produces long-term reduction in levodopa-induced dyskinesia and depression in individuals with Parkinson’s Disease

    T. Falk, S. Richards, M. Bartlett, A. Lind, C. Hsu, S. Sherman (Tucson, USA)

    Objective: An open-label, dose-finding Phase I/II clinical trial was conducted to test safety and tolerability of low-dose ketamine infusion to treat levodopa-induced dyskinesia (LID), and…
  • 2023 International Congress

    Computerized assessment of Handwriting in Parkinson’s Disease Before and After Dopaminergic Medication

    L. Diaz-Feliz, P. Sanz-Cartagena, M. Faundez-Zanuy, J. Arbelo-Gonzalez, P. Garcia-Ruiz (Las Palmas, Spain)

    Objective: Computerized assessment of dysgraphia to evaluate dopaminergic medication effects on the handwriting of newly diagnosed PD patients. Background: Dysgraphia is a common motor symptom…
  • 2023 International Congress

    Gender-specific differences of gait in parkinsonian syndromes

    V. Sidoroff, F. Jagusch, P. Bachmann, N. Roth, N. Hergenröder-Lenzner, I. Teckenburg, A. Ibrahim, S. Büchner, D. Benninger, K. Seppi, F. Krismer, B. Eskofier, J. Winkler, J. Klucken, K. Aminian, H. Gassner, G. Wenning, C. Raccagni (Innsbruck, Austria)

    Objective: The aim of this study was to further assess gender-specific gait and balance differences related to fall frequency in APD and IPD patients. Background:…
  • 2023 International Congress

    Associations of IL-1β and IL-6 gene polymorphisms with Parkinson’s disease(PD)

    M. Ben Mahmoud, S. Fray, H. Jamoussi, N. Ben Ali, M. Fredj, S. Fezai (Tunis)

    Objective: We aim to explore the associations of IL-1β and IL-6 gene polymorphisms with the pathogenesis of PD and with clinical features of motor and…
  • 2023 International Congress

    Clinical features and phenoconversion risk in women with isolated REM sleep behavior disorder

    C. Alexandres, S. Mccarter, G. Tabatabai, L. Leclair-Visonneau, J. Feemster, T. Gossard, P. Timm, D. Sandness, J. Jagielski, E. Strainis, D. Carvalho, M. Junna, M. Lipford, J. Moore, M. Tippmann-Peikert, M. Silber, B. Boeve, E. ST. Louis (Rochester, USA)

    Objective: To determine features predictive of differential phenoconversion rates in isolated REM sleep Behavior Disorder (iRBD) to a defined neurodegenerative disease (NDD). Background: iRBD is…
  • 2023 International Congress

    Deep Brain Stimulation in Parkinson’s Disease: real-world outcomes at a single centre

    B. Lonergan, M. Ciocca, A. Bocum, D. Nandi, P. Bain, G. Charlesworth, N. Pavese, Y. Tai (London, United Kingdom)

    Objective: To describe the clinical outcomes in PD patients following DBS and analyse whether certain demographic and clinical factors are associated with poor outcomes. Background:…
  • 2023 International Congress

    Early neurotransmitters changes in Parkinson’s disease with REM sleep behaviour disorder

    D. Urso, B. Tafuri, S. Nigro, V. Gnoni, I. Rosenzweig, K. Ray Chaudhuri, G. Logroscino (Tricase, Italy)

    Objective: In this study, we aimed to comprehensively investigate the early neurotransmitters changes in a cohort of de novo Parkinson's disease (PD) patients with and…
  • « Previous Page
  • 1
  • …
  • 53
  • 54
  • 55
  • 56
  • 57
  • …
  • 186
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • #23862 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley